1. Avinger Enrolls First European PAD Patient in CONNECT II Global Clinical Trial

    Avinger Enrolls First European PAD Patient in CONNECT II Global Clinical Trial

    Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with Peripheral Artery Disease (PAD), announces the enrollment of the first European patient in the CONNECT II global clinical trial. The first patient was enrolled this morning by Dr. Bernhard Reimers at Ospedale di Mirano in Mirano, Italy.  CONNECT II is multi-center, non-randomized global clinical study designed to evaluate the safety and efficacy of Ocelot, Avinger’s first therapeutic catheter to incorporate the real time intravascular imaging technology called Optical Coherence Tomography, or OCT. Currently CE Marked, Ocelot is designed for crossing completely blocked arteries, or Chronic ...

    Read Full Article

    Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Quotes

    1. This is a major milestone for Avinger and a true testament to the perseverance of all our employees and investors. Many people said we couldn't do it...Ocelot and CONNECT II is our first step toward incorporating intravascular imaging into therapeutic catheters. We truly believe this will revolutionize the treatment of vascular disease and amputation prevention.
  3. Topics Mentioned